Medtronic has received the CE mark for its CoreValve system, used for direct aortic and subclavian transcatheter aortic valve implantation in patients with severe aortic stenosis.

This direct treatment option is designed to provide aortic stenosis patients with an alternative therapy to the transfemoral, transapical and subclavian artery approaches.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

Earlier studies showed that the direct aortic approach demonstrates high procedural success rates and overall survival rates.

The new treatment will allow for easier manipulation and placing of the valve because of the short distance from access site to implantation site.

Currently, the Medtronic CoreValve system is limited to investigational use in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Medical Device Network Excellence Awards - The Benefits of Entering

Gain the recognition you deserve! The Medical Device Network Excellence Awards celebrate innovation, leadership, and impact. By entering, you showcase your achievements, elevate your industry profile, and position yourself among top leaders driving medical devices advancements. Don’t miss your chance to stand out—submit your entry today!

Nominate Now